Corvus Pharmaceuticals announced new preclinical data on November 14, 2024, highlighting the potential of soquelitinib, its lead ITK inhibitor program, to prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. This data adds to the growing body of evidence supporting ITK inhibition as a novel therapeutic approach for immune diseases.
In a Fra-2 transgenic mouse model, soquelitinib treatment reduced lung fibrosis, pulmonary hypertension, and the accumulation of Th2 helper T cells. These positive results were further confirmed in a bleomycin lung injury model, which also showed reduced pulmonary fibrosis and Th2 helper T cell infiltration.
The findings provide a strong rationale for evaluating soquelitinib and next-generation ITK inhibitors for fibrotic diseases like systemic sclerosis. This expands the potential indications for soquelitinib, demonstrating its broad utility in modulating immune responses across various conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.